Research Projects & Grants

For Profit Organization

• LJ501-CRH01: A phase 3, placebo-controlled, randomized, double-blind, multi-center study of LJPC-501 in patients with catecholamine-resistant hypotension (CRH), Role: Investigator, La Jolla Pharmaceutical Company, (02/2017 - 02/2018) Status: Completed
• OASIS: A phase 2/3 randomized, double-blind, placebo-controlled, study of the safety and efficacy of talactoferrin alfa in patients with severe sepsis, Role: Investigator, Agennix, Inc., (05/2012 - 05/2013) Status: Completed
• A phase 2 study to evaluate dose and duration of treatment of drotrecogin alfa (activated) using serial measurements of protein C in patients with severe and multiple organ dysfunctions, Role: Investigator, Eli Lilly & Co., (11/2008 - 11/2009) Status: Completed

Internal

• The effects of upper airway resistance syndrome on executive function, Role: Investigator, LLU Dept. of Medicine, (03/2022) Status: Approved
• Etiologies of Apnea of Infancy (AOI): A Follow Up Study, Role: Investigator, LLU Dept. of Pediatrics, (01/2022) Status: Approved
• Clinical factors that would predict the diagnosis and severity of sleep disordered breathing (SDB) which includes OSA, and Sleep related hypoxemia in Patients with Interstitial Lung Disease (ILD), Role: Investigator, LLU Dept. of Medicine, (07/2021) Status: Approved